Noxopharms Sofra assets to be presented at global conference
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Noxopharm Ltd. announces that its Sofra assets will be presented at an upcoming global conference focused on influenza prevention and treatment. The presentation will highlight how Noxopharm's novel oligonucleotides from the Sofra technology platform can enhance the delivery of self-amplifying mRNA vaccines. Noxopharm's CEO emphasized the platform's versatility and its potential applications in various inflammatory and autoimmune diseases. The conference will feature leading experts in virology and vaccine research, fostering collaboration in the field.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Noxopharm
- Noxopharm progresses US regulatory strategy
- New data shows SOF-SKN active ingredient efficacy
- Innovative collaboration further expands Sofra platform
- March 2026 Quarterly Activities Report and Appendix 4C
- Positive SOF-SKN dosing data shows prolonged skin retention
Later from Noxopharm
- New data confirms cancer-fighting potential
- SOF-SKN manufacturing begins to ensure clinical trial readi
- Quarterly Activities/Appendix 4C Cash Flow Report
- New preclinical data supports immuno-oncology approach
- Appendix 4E - Preliminary Financial Report
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm